Table 1

Baseline characteristics of 291 patients at the time of completing the MISS
Characteristic Value in patient sample
Sex, female 181 (62.2)
Age, mean +/- SD years 59.4 +/- 12.4
Diagnosis
   Rheumatoid arthritis 249 (85.6)
   Psoriatic arthritis 42 (14.4)
Disease activity
   Disease activity score 28, median (IQR)a 2.5 (1.7 to 3.2)
   Physician’s global assessment, median (IQR), (0 to 10 scale)b 2.0 (1.0 to 3.0)
   Erythrocyte sedimentation rate (mm/hour) 11.0 (5.0 to 22.0)
MTX use
   Route of administration, oral 194 (66.7)
   Dose, mg/week, median (IQR) 20.0 (12.5 to 25.0)
Other medication
   NSAIDs 145 (49.9)
   Proton-pump inhibitors 127 (43.6)
   Anti-emetics 5 (1.7)
   Oral steroids 31 (10.7)
   Other DMARDsc 72 (24.7)

Characteristics are as calculated at the time of completing the MISS except where indicated otherwise. Values are number (%), except where indicated otherwise. aDisease activity score 28 was determined in 266 patients (274 rheumatoid arthritis and 19 psoriatic arthritis patients); bphysician’s global assessment was determined in 268 patients; cof 72 patients on other DMARDs, 26 were on DMARDs (plaquenil, n = 24; leflunomide, n = 2) and 46 were on biologic agents (infliximab, n = 24; adalimumab, n = 10; etanercept, n = 9; abatecept, n = 2; golimumab, n = 1). MISS, methotrexate intolerance severity score; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; DMARDs, disease-modifying anti-rheumatic drugs.

Bulatović Ćalasan et al.

Bulatović Ćalasan et al. Arthritis Research & Therapy 2013 15:R217   doi:10.1186/ar4413

Open Data